Guangzhou Recomgen Biotech Co., Ltd. clinical trials
Acquired by CSPC Pharmaceutical Group Limited, 2022 · source ↗
The registry lists 1 studies whose lead sponsor is Guangzhou Recomgen Biotech Co., Ltd.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated May 25, 2022.
Before and after it joined CSPC Pharmaceutical Group Limited
- First submitted before Guangzhou Recomgen Biotech Co., Ltd. became part of CSPC Pharmaceutical Group Limited
- 1
- First submitted after Guangzhou Recomgen Biotech Co., Ltd. became part of CSPC Pharmaceutical Group Limited
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- Guangzhou Recomgen Biotech Co., Ltd.1 study
Something wrong with this grouping? Tell us on the CSPC Pharmaceutical Group Limited page.
Studies
Recruiting first, then most recently updated. Showing 1 of 1. All CSPC Pharmaceutical Group Limited studies →
- The Efficacy and Safety of rhTNK-tPA in Comparison With Alteplase(Rt-PA) as Fibrinolytic Therapy of Acute STEMICompletedNCT02835534Phase 4
Sponsor listed in the registry: Guangzhou Recomgen Biotech Co., Ltd. · First submitted before Guangzhou Recomgen Biotech Co., Ltd. became part of CSPC Pharmaceutical Group Limited